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ABSTRACT
In this study, we show that the transmembrane glycoprotein Trop-2 is up-
regulated in human prostate cancer (PCa) with extracapsular extension (stages 
pT3/pT4) as compared to organ-confined (stage pT2) PCa. Consistent with this 
evidence, Trop-2 expression is found to be increased in metastatic prostate tumors 
of Transgenic Adenocarcinoma of Mouse Prostate mice and to strongly correlate with 
α5β1 integrin levels. Using PCa cells, we show that Trop-2 specifically associates with 
the α5 integrin subunit, as binding to α3 is not observed, and that Trop-2 displaces 
focal adhesion kinase from focal contacts. In support of the role of Trop-2 as a 
promoter of PCa metastatic phenotype, we observe high expression of this molecule 
in exosomes purified from Trop-2-positive PCa cells. These vesicles are then found 
to promote migration of Trop-2-negative PCa cells on fibronectin, an α5β1 integrin/
focal adhesion kinase substrate, thus suggesting that the biological function of Trop-
2 may be propagated to recipient cells. In summary, our findings show that Trop-2 
promotes an α5β1 integrin-dependent pro-metastatic signaling pathway in PCa cells 
and that the altered expression of Trop-2 may be utilized for early identification of 
capsule-invading PCa.
INTRODUCTION
The molecular mechanisms underlying the early 
phases of tumor invasion are not completely understood, 
although it is largely believed that acquisition of enhanced 
capacity to migrate through the extracellular matrix 
(ECM) is a critical step for the onset of the metastatic 
cascade. When diagnosed at a non-invasive stage, prostate 
cancer (PCa) is generally curable by surgical removal of 
the prostate gland. However, when PCa cells acquire the 
ability to break through the external capsule and invade 
the surrounding tissues, the chances to eradicate the 
disease by radical prostatectomy are reduced, resulting in 
lower overall survival rates for patients with metastatic 
disease. Widely accepted tumor staging criteria establish 
that stage pT2 identifies PCa still confined within the 
prostatic gland, whereas stages pT3/pT4 refer to PCa that 
has spread through the capsule and has eventually invaded 
adjacent structures [1, 2]. Traditional disease monitoring 
approaches, including circulating prostate specific antigen 
(PSA) levels or Gleason scoring, do not discriminate 
between stage pT2 and stages pT3/pT4 [1, 2], thus 
hampering a central tenet for cancer patient stratification 
[3]. Therefore, developing molecular biomarkers that 
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could identify specific stages of PCa progression remains 
an urgent, unmet medical need.
Previous studies have reported that the expression 
profile of many integrins, receptors for ECM substrates, 
becomes aberrant during cancer progression [4, 5]. In 
particular, the α5β1 integrin heterodimer plays a pivotal 
role in development and progression of several types 
of carcinomas, including PCa [6, 7], and its expression 
correlates with reduced disease-free survival in several 
malignancies [7-9]. The α5β1 integrin is implicated in 
cell proliferation and growth [10]. A function-blocking 
antibody against α5β1 integrin significantly reduces 
tumor burden and metastasis in ovarian cancer models 
[7]. Additional studies demonstrate that the α5β1 integrin 
directly supports cell migration/invasion and metastasis 
[11, 12]. 
Metastatic dissemination is also promoted by 
exosomes, vesicles of endosomal origin, which are 
believed to generate a suitable microenvironment in the 
pre-metastatic niche [13, 14] by mediating horizontal 
transfer of genetic material [15] as well as of signaling 
molecules [14].
The epithelial transmembrane glycoprotein Trop-
2 functions as a key regulator of β1 integrin activities 
by inducing cell detachment from ECM substrates 
and promoting motility of PCa cells [16, 17]. Trop-
2 overexpression has been consistently linked to poor 
prognosis in many human cancers [18-21], suggesting a 
potential role of this molecule in metastatic dissemination. 
Specifically, we have previously shown that Trop-2 
inhibits localization of β1 integrins in focal adhesions 
(FAs) and induces hyperphosphorylation of focal adhesion 
kinase (FAK), deregulating cell-ECM interactions [17]. 
Altogether, the experimental findings presented here 
show that Trop-2 is a novel marker of capsule-invasive 
PCa, is found in PCa cell exosomes and may function as 
mediator of PCa cell motility and metastasis.
RESULTS
Trop-2 expression is increased in stages pT3/pT4 
of human PCa
Our previous findings demonstrate a role of Trop-
2 as an anti-adhesive and pro-migratory regulator in PCa 
[16, 17]. Here, we hypothesized that up-regulation of 
Trop-2 promotes escape of PCa cells from the primary 
tumor microenvironment and accelerates the onset 
of the metastatic cascade. Hence, we performed an 
immunofluorescence (IF) analysis of human PCa tissues; 
as depicted in Figure 1A, an abundant distribution of 
Trop-2 is found in membrane rims of the transformed 
cell population, whereas no reactivity is detected in the 
stromal compartment. We next analyzed Trop-2 expression 
levels in human PCa tissues by immunohistochemistry 
(IHC) using a Tissue Microarray (TMA) containing 104 
cores from stage pT2 (organ-confined) and 44 cores from 
stages pT3/pT4 (PCa with extracapsular extension) cancer 
specimens collected from radical prostatectomies (Table 
1). An example of Trop-2 expression in stages pT3 and 
pT2 of PCa is shown in Figure 1B. The expression of 
Trop-2 in these specimens was evaluated as low (IHC 
score <1.5) or high (IHC score ≥1.5) and is reported 
in Table 1. In these experiments, we observe strong 
expression of Trop-2 in 29.8% of pT2 stage and 81.8% in 
pT3/pT4 stage samples (Fisher’s exact test P = 0.0002). 
We analyzed in parallel the frequency of cases with high 
Gleason score (8-10) in stage pT2 and stages pT3/pT4 and 
found that the differences are not statistically significant 
(Fisher’s exact test P = 0.0940). Our results show that 
Table 1: Correlation of Trop-2 expression with pT3/pT4 in extracapsular invasive human 
prostate cancer
Score pT2(N = 104)
pT3/pT4
(N = 44) P
n (% of N) n (% of N)
Trop-2 IHC Score 0.0002
< 1.5 73 (70.2) 8 (18.2)
≥ 1.5 31 (29.8) 36 (81.8)
Gleason Score 0.0940
6-7 72 (69.2) 24 (54.6)
8-10 32 (30.8) 20 (45.4)
Expression of Trop-2 was evaluated by IHC using 148 PCa specimens as described in Methods. Samples were categorized 
in groups based on Trop-2 expression measured using IHC (< 1.5 and ≥ 1.5) or Gleason (6-7 and 8-10) scores. P, P value 
was determined as described in the Methods section.
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Trop-2 expression correlates with the stages pT3/pT4 in 
extracapsular invasive human PCa. 
Trop-2 is up-regulated in prostate tumors of 
metastatic Transgenic Adenocarcinoma of Mouse 
Prostate (TRAMP) mice and forms a complex 
with the α5β1 integrin in PCa cells 
Although mouse models of spontaneous PCa 
progression to metastasis are limited [22], the TRAMP 
model is known to develop aggressive and metastatic 
PCa [23]. We observe Trop-2 expression in metastatic 
prostate tumors of TRAMP mice using IF staining of 
prostate tumor tissue sections (Figure 2A). Macroscopic 
organ dissection of TRAMP mice (n = 69) was performed 
and primary tumors as well as metastases were analyzed. 
Figure 2B shows a representative normal genito-urinary 
(GU) (top left panel) and a primary tumor (bottom left 
panel), and also metastases in lung (top right panel) and 
liver (bottom right panel). Hematoxylin and Eosin (H&E) 
analysis of non-metastatic (top left panel) and metastatic 
(bottom left panel) primary tumors is shown in Figure 2C. 
Analysis of lung (Figure 2C, top right panel) and liver 
(Figure 2C, bottom right panel) metastases are also shown. 
We next analyzed the expression levels of Trop-
2 and of α5, β1, β5, and αv integrin subunits in this 
experimental model, and compared metastatic (n = 4) 
with non-metastatic primary tumors (n = 4). As shown 
in Figure 3A, Trop-2 is highly expressed in metastatic 
tumor samples, but it is undetectable or expressed at low 
levels in non-metastatic tumors. Similarly, both α5 and β1 
integrin subunits are strongly up-regulated in metastatic 
prostate tumors as compared with non-metastatic tumors. 
These changes are found to be specific, as β5, another 
integrin subunit, does not show appreciable variations in 
expression between metastatic and non-metastatic tumors. 
The αv integrin subunit, which does not associate with 
Trop-2 in PCa cells [16], was also preferentially expressed 
in metastatic tumors, suggesting the existence of additional 
regulatory mechanisms of this integrin subunit in PCa. 
Since Trop-2 inhibits β1 integrin-mediated PCa cell 
adhesion to fibronectin (FN) [17] and induces migratory 
phenotypes on this ECM ligand [16], we tested the ability 
of Trop-2 to interact with α5β1. Co-immunoprecipitation 
experiments performed using PC3 human PCa cells 
demonstrate that Trop-2 specifically associates with the 
α5 integrin subunit (Figure 3B). In contrast, another β1-
associated subunit, α3, does not interact with Trop-2 
(Figure 3C). These results provide a biochemical basis for 
Figure 1: Trop-2 localization and expression in PCa. A. Localization of Trop-2 as investigated by IF staining and confocal 
microscopy in human PCa (pT3 stage, Gleason Score 9). B. Representative IHC staining for Trop-2 using specimens from patients at pT3 
(left) and pT2 (middle) stages of PCa is shown. A non-immune IgG was used as negative control on a stage pT3 section (right). Bars, 100 
µm. 
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the ability of Trop-2 to specifically regulate α5β1 integrin 
functions. 
Trop-2 displaces focal adhesion kinase from focal 
contacts
Recent findings from our group have shown that 
Trop-2 inhibits accumulation of α5β1 integrin at FA 
sites [16], and promotes FAK activation [17]. To test this 
model, we stably silenced the expression of Trop-2 in 
PCa cells and looked at the dynamics of FAK subcellular 
distribution. As shown in Figure 4 (right panel), the 
average number of FAK-containing FA sites is found to be 
178.60 ± 0.53 per cell in PC3/Trop-2 shRNA cells (FAK-
containing FAs, n = 5,358/30 cells) as compared with 
30.57 ± 0.4 per cell in PC3/control shRNA (Ctr.shRNA) 
cells (FAK-containing FAs, n = 917/30 cells). Conversely, 
the average number of vinculin-containing FAs is 107.87 
± 0.50 per cell in PC3/Trop-2 shRNA cells (FAs, n = 
3,236/30 cells) as compared with 110.53 ± 0.43 per cell in 
PC3/Ctr.shRNA cells (FA, n = 3,316/30 cells), confirming 
the specificity of the observed response (Figure 4). 
Figure 2: Analysis of Trop-2 expression in metastatic PCa from TRAMP mice. A. IF analysis of Trop-2 expression in 
metastatic prostate tumors from TRAMP mice (top). Cell nuclei were counterstained with DAPI. A non-immune goat IgG was used as a 
negative control Ab (bottom). B. Representative images of a dissected normal genito-urinary (GU) system (top left), primary prostate tumor 
(bottom left), and lung (top right) and liver (bottom right) macroscopic metastases. Seminal vesicles (black arrow); metastases (yellow 
arrowheads). C. H&E staining of non-metastatic (top left), metastatic primary prostate tumors (bottom left), and of metastases in lungs (top 
right) and liver (bottom right). 
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Figure 3: Correlation of Trop-2 and α5β1 integrin expression in murine PCa. A. Analysis of α5, β1 (top), αv and β5 (bottom) 
integrin subunits, as well as of Trop-2 (bottom) expression by IB using protein lysates from non-metastatic (left) and metastatic (right) 
prostate tumors collected from TRAMP mice. ERK1, control of protein loading. B. Protein lysates of PC3 cells endogenously expressing 
Trop-2 were immunoprecipitated using an Ab targeting Trop-2; a non-immune mouse IgG was used as a negative control Ab (Neg. Ctr.). 
The immunoprecipitates were then separated by SDS-PAGE and analyzed by IB for detection of the α5 integrin subunit and Trop-2. C. 
Protein lysates of PC3 cells were immunoprecipitated using Abs targeting β1 integrins or Trop-2; a non-immune mouse IgG was used as a 
negative control Ab (Neg. Ctr.). The immunoprecipitates were then analyzed by IB for detection of the α3 integrin subunit. 
Figure 4: Trop-2-dependent modulation of FAK localization. Localization of vinculin and FAK in PC3/Ctr.shRNA and PC3/
Trop-2 shRNA cells seeded on FN was analyzed by IF (left). Vinculin (Vin)- and FAK-containing FAs were counted, and the average 
numbers per cell are shown in the bar graph (right). Error bars, SEM. **, Student’s t-test P < 0.001. 
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Trop-2 is recruited in PCa exosomes that stimulate 
cell migration on FN
Release of exosomes from cancer cells has been 
shown to efficiently contribute to induction of metastatic 
dissemination by favoring intercellular communication 
[14, 24]. We hypothesized that Trop-2 may be recruited 
to these cellular compartments, where β1 integrins are 
also found [24-26]. Therefore, we isolated exosomes 
from PC3 culture supernatants and investigated by 
immunoblotting (IB) whether Trop-2 is recruited in these 
organelles as described in previous proteomic studies 
[27, 28]. Exosome preparations were characterized by 
IB analysis of exosomal markers: CD63, CD81 (Figure 
5B); as control, IB analysis of Calnexin was performed to 
exclude contamination of endoplasmic membranes (Figure 
5A). Our results show specific recruitment of Trop-2 in 
exosomes (Figure 5A). To investigate whether exosomal 
Trop-2 might affect cell migration on FN, we incubated 
Trop-2-negative cells, PC3Trop-2- or LNCaP cells, with or 
without exosomes purified from PC3 cells which either 
express Trop-2 (Parental, Ctr.shRNA) or lack Trop-2 
(Trop-2 shRNA). After confirming down-regulation of 
Trop-2 in exosomes, characterized by IB analysis of the 
exosomal marker CD63 (Figure 5B), we next performed 
migration assays FN as substrate. We show that 24 h 
treatment with Trop-2 containing exosomes increases 
cell migration on FN of both cell lines (Figure 5C). These 
findings suggest that a functional Trop-2/α5β1 integrin 
complex may accumulate in exosomes and stimulate 
migration of recipient cells. 
Figure 5: PC3 exosome uptake by PCa cells enhances cell migration on FN in a Trop-2-dependent manner. A. Analysis 
of Trop-2 levels in purified PC3 exosomal lysates separated by SDS-PAGE in non-reducing conditions and immunoblotted using an Ab to 
Trop-2; CD63 and CD81 were used as positive exosomal markers while calnexin (CANX) was used as a negative marker for exosomes. 
Exo, exosomes; TCL, total cell lysates. B. IB analysis of Trop-2 expression in exosomes secreted by PC3 cells (Ctr.shRNA and Trop-2 
shRNA) using an Ab to Trop-2; CD63 was used as positive exosomal markers while calnexin (CANX) was used as a negative marker for 
exosomes. Exo, exosomes; TCL, total cell lysates. C. Migration assays of PC3Trop-2- (left) or LNCaP (right) cells either untreated or treated 
with 10 µg/ml of PC3 exosomes (Exo) in which Trop-2 is expressed (Parental and Ctr.shRNA) or down-regulated (Trop-2 shRNA). Left, 
χ2 test ; right, Student’s t-test. *, P ≤ 0.05.
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DISCUSSION
In this study, we demonstrate for the first time that 
Trop-2, an anti-adhesive and pro-migratory transmembrane 
protein, is up-regulated in human PCa with extracapsular 
extension (stages pT3/pT4) as compared to organ-
confined (stage pT2) PCa, suggesting that this molecule 
plays a crucial role during cancer progression toward a 
metastatic phenotype. Mechanistically, we show that Trop-
2 specifically binds the α5β1 integrin heterodimer and 
induces rearrangement of FA sites through displacement 
of FAK, thus perturbing the integrin signaling axis which 
is a major regulator of FA [29]. We finally find Trop-2 
expression in exosomes secreted from PCa cells and 
demonstrate that Trop-2-containing exosomes stimulate 
migration of recipient Trop-2-negative cells on the α5β1 
integrin substrate, FN. 
The correlation between Trop-2 and disease 
progression suggests that this molecule is a novel 
biomarker of aggressive disease. During development, 
Trop-2 is expressed in the trophoblast, an actively 
invasive tissue at the interface between fetal and 
maternal circulation [30], whereas expression of this 
molecule in the adult is confined to a restricted number 
of tissues [21]. This pathway becomes exploited in 
malignancy, where Trop-2 is overexpressed in several 
human carcinomas, promotes accelerated tumor growth 
[21, 31], and correlates with unfavorable prognosis [18-
20]. Our findings reinforce a role of this pathway in the 
progression from organ-confined to disseminated cancer 
and this phenotype appears to be more insightful than 
Gleason scores in the histopathological analysis of stages 
pT2 and pT3/pT4. It remains to be investigated whether 
Trop-2 overexpression may be predictive of biochemical 
recurrence after prostatectomy as Gleason scores are poor 
predictors of recurrence [32].
We find that the up-regulation of Trop-2 in metastatic 
tumors from TRAMP mice correlates with expression 
of β1 integrins (Figure 3A). While the mechanisms of 
Trop-2 up-regulation during disease progression are 
not known, we hypothesize that β1 integrins and Trop-
2 expression may be co-regulated. Specifically, since 
previous studies from our group have shown that Insulin-
like Growth Factor-1 Receptor (IGF-IR) plays a critical 
role in regulating β1 integrin expression and since the 
absolute levels of IGF-IR increase during PCa progression 
in TRAMP tumors [33-35], we propose that IGF-IR may 
be an upstream regulator of Trop-2/β1 integrin levels in 
metastasis-prone tumor types. 
The proposed mechanism of metastatic 
dissemination, as suggested here, requires also up-
regulation of the α5 integrin subunit expression and 
appears specific since it does not affect the α3 integrin 
subunit. The acquisition of invasive potential by 
transformed cells has been linked to loss of E-cadherin-
dependent cell-cell contacts, epithelial-to-mesenchymal 
transition [36] and consequent up-regulation of α5 [7]. 
Consistently, we observe that α5 is overexpressed in 
metastatic versus non-metastatic PCa using TRAMP mice 
as a model of disease progression. This may involve, 
in addition to the previously reported ability of α5β1 to 
promote epithelial-to-mesenchymal transition during 
cancer progression [7], a direct role in leading PCa 
invasion through recognition sequences in FN for the 
α5 subunit [37]. Our previous findings that the reduced 
adhesive phenotype induced by Trop-2 results in a higher 
rate of cell migration on FN [16] are consistent with a 
model of Trop-2 modulation of α5β1 integrin signaling 
and selective displacement of FAK from FAs, that does not 
require changes in FAK expression as previously reported 
by our group [17]. 
We finally describe a novel mechanism involving 
accumulation of the Trop-2/β1 complex in secreted 
exosomes and demonstrate that exosomes containing 
Trop-2 impact neighboring tumor cells by enhancing their 
ability to migrate. These data suggest that therapeutics 
which interfere with the production, transfer or uptake 
of Trop-2-containing exosomes may attenuate tumor 
progression and metastasis.
Although more work is needed to fully elucidate the 
pro-invasive signaling pathways mediated by Trop-2 in 
PCa cells, the data presented here suggest that modulation 
of the Trop-2/α5β1 complex may provide new insights in 
the functional stratification of PCa patients with higher 
metastatic propensity and, therefore, in need of more 
aggressive treatments.
MATERIALS AND METHODS
Cells and culture conditions
Cell lines and transfectants, as well as culture 
conditions have been described previously [16, 17]. 
Authentication of the cell lines was provided with their 
purchase from American Type Culture Collection. PC3/
Ctr.shRNA and PC3/Trop-2 shRNA cells were generated 
as described previously [16, 21].
Mice
TRAMP mice, expressing SV40 large T antigen into 
the prostatic epithelium, were generated and characterized 
as described [23]. 23-54 week-old metastatic and non-
metastatic TRAMP mice were used to isolate tumor 
samples and perform IB analysis. Distant sites were: 
liver and lungs. All mice were maintained under specific 
pathogen-free conditions. Care and handling of animals 
was in compliance with IACUC experimental protocols.
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Reagents and antibodies
The T16 mouse monoclonal antibody (mAb) 
against Trop-2 (gift of Dr. S. Alberti) and the TS2/16 
mAb against β1 integrin (HB-243, ATCC) were used for 
IP. The following Abs were used for IB: mAbs against β1 
integrin subunit (610468, BD Transduction Laboratories), 
CD63 (Ab8219, Abcam), CD81 (Ab23505, Abcam); goat 
polyclonal Abs (pAbs) against human and murine Trop-2 
(AF650 and AF1122, R&D Biosystems); rabbit antisera 
against α3 and αv integrin subunits; rabbit pAbs against 
α5 integrin subunit (sc-10729, Santa Cruz Biotechnology), 
β5 integrin subunit (AB1926, Millipore), Calnexin (sc-
11397, Santa Cruz Biotechnology) and ERK1/2 (sc-93, 
Santa Cruz Biotechnology). The goat pAb against human 
Trop-2 (AF650, R&D Biosystems), a mAb to Vinculin 
(MAB1624, Millipore) and a mAb to FAK (05-537, 
Millipore) were used for IF. A goat pAb against human 
Trop-2 (R&D Biosystems) was used for IHC. Non-
immune goat IgG (SantaCruz), non-immune rabbit IgG 
(Sigma) and non-immune mouse IgG (Pierce) were used 
as negative control Abs. FN purification from human 
plasma has been previously described [17]. 
Immunohistochemical analysis
TMAs were constructed at the Vancouver Prostate 
Cancer Centre (Vancouver, Canada) from 74 men with 
newly diagnosed, previously untreated, clinically localized 
high-risk PCa, who underwent radical prostatectomy at 
the same Center. Ethical approval was obtained from the 
Institutional Ethical Review Board.
Specimens were identified for benign and cancerous 
sites and marked in donor paraffin blocks using matching 
H&E-stained reference slides. The TMAs were constructed 
using a manual tissue microarrayer (Beecher Instruments, 
Silver Spring, MD, USA). Each marked block for benign 
and cancerous sites was sampled two times with a core 
diameter of 0.6 mm arrayed in a rectangular pattern with 1 
mm between the center of each core, creating a duplicate 
TMA layout with a total of 148 cores. The TMA paraffin 
block was sectioned into 5-µm sections and mounted on 
positively charged slides.
IHC staining was conducted using a goat pAb to 
Trop-2 (AF650, R&D Biosystems, dilution 1:25) by a 
Ventana autostainer model Discover XTTM (Ventana 
Medical System, Tuscan, AZ, USA) with an enzyme-
labelled biotin-streptavidin system and solvent-resistant 
3,3’-diaminobenzidine Map kit. The slides were scanned 
on a BLISS system (Bacus Laboratory, North Lombard, 
IL, USA) and scored from 0 to +3 by a pathologist (L.F.) 
based on the staining intensity and the proportion of cells 
stained. Normal goat IgG was used as negative control Ab. 
All comparisons of staining intensities were made at 200X 
magnifications.
Immunofluorescence and confocal microscopy
Antigen retrieval was performed on rehydrated 
formalin-fixed paraffin-embedded sections from human 
or TRAMP mice PCa samples by incubation in 10 mM 
Sodium Citrate Buffer (pH 6.0) at 95°C for 23 min. The 
sections were blocked for 1 h at room temperature with 
PBS / 5% BSA. Staining was performed by incubation 
of tissue samples with primary Abs (1:100) for 1 h at 
room temperature, followed by incubation with Alexa 
Fluor 633-Donkey anti goat (1:250) for 20 min at room 
temperature. Nuclei were counterstained using DAPI. 
After three washes, coverslips were mounted on the 
sections using Pro-Long anti-fade reagent (Invitrogen), 
and slides were analyzed on an inverted confocal 
microscope (LSM510, Carl Zeiss). Immunofluorescence 
analysis of PC3 cells using Alexa Fluor 488 goat anti-
mouse (1:250) for 60 min at room temperature was 
performed as described [16].
Generation of tumor lysates
Tumor lysates were prepared by homogenizing the 
tissues on ice using the following lysis buffer: 100 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 5% SDS, 0.1% Triton 
X-100, 1 mM benzamidine, 10 µg/mL Soybean Trypsin 
Inhibitor, 10 µg/mL leupeptin, 1 mM PMSF, 1 µg/mL 
pepstatin A, and 1 µM calpain inhibitor. The lysates were 
boiled for 5 min and centrifuged at 13,000 rpm for 20 
min. Supernatants were collected and protein content was 
determined using the DC Protein Assay Kit (Bio-Rad). 
The protein samples (50 µg per lane) were separated by 
SDS-PAGE and transferred onto PVDF membranes for IB.
Isolation and immunoblotting analysis of PCa 
exosomes
Exosomes were isolated from PCa cells as 
described [24, 38]. Purified exosomes were lysed with 
radioimmunoprecipitation assay buffer (10 mM Tris-HCl 
at pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% 
Triton X-100, and 1% sodium deoxycholate) supplemented 
with protease inhibitors. The protein samples (10 µg per 
lane) were separated by SDS-PAGE under non-reducing 
conditions and transferred onto PVDF membranes for IB.
Immunoprecipitation
To collect nuclear and cytoplasmic fractions, cells 
were washed with cold PBS and lysed by scraping in 
20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1mM CaCl2, 
1mM MgCl2, 1% NP-40, 1 mM benzamidine, 10 µg/
ml leupeptin, 1 mM PMSF, 1 µg/ml pepstatin A, 1 µM 
calpain inhibitor, 1mM Na3VO4, 1 mM Na4O7P2. The 
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cells were subjected to 3 cycles of sonication (15 sec 
each) on ice. After 15 min incubation on ice, lysates were 
centrifuged at 12,000g for 10 min, and supernatants were 
collected and pre-cleared by two consecutive incubations 
with protein G-Sepharose at 4ºC for 45 min. Binding 
to specific Abs was performed by incubation at 4ºC for 
3 h, followed by incubation with protein G-Sepharose 
at 4ºC for 1 h. After six washes with lysis buffer, 
immunocomplexes were eluted with 100 mM glycine pH 
2.5, followed by pH neutralization using Tris to a final 
concentration of 50 mM. The immunocomplexes were 
then separated by SDS-PAGE, transferred onto PVDF 
membrane, and subjected to analysis by IB. 
Exosome treatment and migration assay
Cell treatment with exosomes was performed as 
previously described [24]. Briefly, LNCaP and PC3Trop-2- 
cells were serum starved for 18 h, then treated for 24 h 
with 20 µg/ml of exosomes obtained from PC3 cells. The 
cells treated with PC3-derived exosomes were trypsinized, 
extensively washed with PBS and subsequently plated to 
perform the migration assay. Cell migration assays on 
FN has been performed as previously described using 
Millicell inserts (Millipore) with 8 (for LNCaP) or 12 
µm (for PC3Trop-2-) pores [16]. Briefly, chambers were 
coated on both top and bottom layers with FN (10 µg/
mL) or 1% BSA overnight at 4ºC. After cell detachment 
and trypsin inactivation, cells were seeded on coated 
transwell chambers at 37°C for 6 h. After fixation with 
3.7% paraformaldehyde (PFA), cells attached on both 
layers of the porous filter were stained with 1 µg/mL 
4’,6-diamidino-2-phenylindole (DAPI) and pictures of 
nuclei were acquired by fluorescence microscopy. Then, 
cells on the top layer were removed using a cotton swab, 
and pictures of nuclei from cells migrated to the bottom 
layer were acquired. For each group of PC3Trop-2- cells 
treated with or without exosomes, the ratio between 
number of cells migrated onto the bottom layer and total 
(top + bottom) number of cells attached on the filter was 
calculated. For LNCaP cells, only the total number of cells 
attached on the bottom layer was calculated.
Statistical analysis
For patients’ samples, Fisher’s exact test was used to 
examine the association between dichotomized biomarkers 
(Trop-2) and PCa stage (Gleason score). For FA analysis, 
t-test was used to evaluate the average numbers of FA per 
cell between PC3/Ctr.shRNA and PC3/Trop-2 shRNA 
cells. For migration assays χ2 tests and t-test were used 
to compare the migration between treatments. Stata 12.0 
(StatCORP LP, College Station, TX, USA was used 
for data analysis  P ≤ 0.05 was considered as statistical 
significance.
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